|
|
 |
 |
| |
 Printable version |
Epigenetic perturbations and cancer: innovative therapeutic strategies against cancer |
Bulletin du Cancer. Volume 97, Number 11, 1265-74, novembre 2010, Synthèse
|
 Résumé
Article gratuit
|
Author(s) : N Reynoird, S Rousseaux, S Khochbin |
Summary : A complex system of molecular milestones ensures labelling of the genome, driving its organization and functions. These milestones correspond to particular marks associated to active and repressed genes, as well as to non-coding regions or those containing repetitive sequences. Most of these marks are chemical modifications of DNA, corresponding to cytosine methylation, or various posttranslational modifications of histones, the proteins which package the genome. These chemical modifications of DNA or histones are reversible and are catalysed and removed by enzymatic activities associated with factors ensuring critical cellular functions. Indeed, these enzymes are directly connected with signalling pathways, sensing extra- and intracellular environments. Altogether these mechanisms globally control the expression status of genes in each cell, meaning that certain genes are kept active, while most of the genome remains silent. Subtle metabolic changes or intra and extracellular modifications, by altering the marking associated to genes, can have long-term consequences on their expression status. Genes coding for essential regulators of cellular proliferation and differentiation could be among these genes, such as tumor suppressor genes for instance. Hence the knowledge of all these so-called “epigenetic” mechanisms will shed new light on the environmental impact on the control of gene expression and associated diseases, including malignant transformation. The understanding of these mechanisms will also pave the way for innovative therapeutic strategies to fight cancer. This review is aiming to give an overview to the reader of the relevance of epigenetic mechanisms for the understanding and treatment of cancer. |
Keywords : chromatin, cancer/testis factors, HDAC inhibitors, acetylation, BRDT, NUT, ATAD2 |
|
